目的 研究血清F2-异前列腺素（F2IP）、同型半胱氨酸（Hcy）、胞质型磷脂酶A2（cPLA2）与男性勃起功能障碍的关系。 方法 以2020年1月至2025年4月内蒙古医科大学附属医院收治的198例勃起功能障碍患者作为病例组，选取同期在我院进行体检的生殖功能和性功能均正常的198名体检者作为对照组，统计两组血清F2IP、Hcy、cPLA2、性激素水平及国际勃起功能指数（IIEF）评分，分析血清F2IP、Hcy、cPLA2对男性勃起功能障碍的诊断价值；根据IIEF评分将勃起功能障碍患者分为重度组（45例）、中度组（88例）、轻度组（65例），比较3组血清F2IP、Hcy、cPLA2、性激素水平，并分析勃起功能障碍患者血清F2IP、Hcy、cPLA2水平与血清性激素水平及IIEF评分的相关性。 结果 病例组血清F2IP、Hcy、cPLA2、卵泡刺激素、黄体生成素水平高于对照组，血清睾酮水平及IIEF评分低于对照组（P < 0.05）。血清F2IP、Hcy、cPLA2三者联合诊断勃起功能障碍患者的曲线下面积（AUC）值高于三者单独检测（P < 0.05），其敏感度和特异度分别为88.38%、84.34%。轻度组、中度组、重度组血清F2IP、Hcy、cPLA2、卵泡刺激素、黄体生成素水平呈升高趋势，血清睾酮水平呈降低趋势（P < 0.05）。勃起功能障碍患者血清F2IP、Hcy、cPLA2水平与血清睾酮水平及IIEF评分呈负相关关系（r = -0.573、-0.618、-0.549、-0.516、-0.553、-0.581，P < 0.05），与血清卵泡刺激素、黄体生成素水平呈正相关关系（r = 0.571、0.650、0.650、0.511、0.648、0.547，P < 0.05）。 结论 勃起功能障碍的发生可引起患者血清F2IP、Hcy、cPLA2水平升高及血清性激素水平异常，且血清F2IP、Hcy、cPLA2联合可提高对勃起功能障碍的诊断价值，同时患者血清F2IP、Hcy、cPLA2水平与其血清性激素水平、病情严重程度存在明显相关性。

Objective To investigate the relationship between serum F2-isoprostaglandin （F2IP）， homocysteine （Hcy）， cytoplasmic phospholipase A2 （cPLA2） and male erectile dysfunction. Methods A total of 198 patients with erectile dysfunction who were admitted to the Affiliated Hospital of Inner Mongolia Medical University from January 2020 to April 2025 were selected as the case group. Meanwhile， 198 physical examinees with normal reproductive and sexual functions who underwent physical examinations in our hospital during the same period were selected as the control group. The levels of serum F2IP， Hcy， cPLA2， sex hormones， and the score of the international index of erectile function （IIEF） were measured and recorded in the two groups. Subsequently， the diagnostic value of serum F2IP， Hcy， and cPLA2 for male erectile dysfunction was analyzed. Based on the IIEF score， the patients with erectile dysfunction were classified into the severe group （45 cases）， the moderate group （88 cases）， and the mild group （65 cases）. The levels of serum F2IP， Hcy， cPLA2， and sex hormones were compared among the three groups， and the correlation between the levels of serum F2IP， Hcy， cPLA2， sex hormones， and the IIEF score in patients with erectile dysfunction was analyzed. Results The levels of serum F2-isoprostane （F2IP）， homocysteine （Hcy）， cytosolic phospholipase A2 （cPLA2）， follicle-stimulating hormone （FSH）， and luteinizing hormone （LH） in the case group were significantly higher than those in the control group， while the serum testosterone level and International Index of Erectile Function （IIEF） score were significantly lower than those in the control group （P < 0.05）. The area under the curve （AUC） of the combined detection of serum F2IP， Hcy， and cPLA2 in the diagnosis of erectile dysfunction was higher than that of each biomarker alone （P < 0.05）， with the sensitivity and specificity being 88.38% and 84.34%， respectively. In the mild， moderate， and severe groups， the levels of serum F2IP， Hcy， cPLA2， FSH， and LH exhibited an increasing trend， whereas the serum testosterone level showed a decreasing trend （P < 0.05）. The levels of serum F2IP， Hcy， and cPLA2 in patients with erectile dysfunction were negatively correlated with the serum testosterone level and IIEF score （r = -0.573， -0.618， -0.549， -0.516， -0.553， -0.581； P < 0.05） and positively correlated with the levels of serum FSH and LH （r = 0.571， 0.650， 0.650， 0.511， 0.648， 0.547； P < 0.05）. Conclusions The occurrence of erectile dysfunction can lead to an increase in the levels of serum F2IP， Hcy， and cPLA2， as well as an abnormality in the levels of serum sex hormones. Moreover， the combination of serum F2IP， Hcy， and cPLA2 can enhance the diagnostic value of erectile dysfunction. Meanwhile， there is a significant correlation between the levels of serum F2IP， Hcy， and cPLA2， the levels of serum sex hormones， and the severity of the disease.